BRPI0712073A2 - cÉlulas produtoras de polipeptÍdio - Google Patents

cÉlulas produtoras de polipeptÍdio Download PDF

Info

Publication number
BRPI0712073A2
BRPI0712073A2 BRPI0712073-7A BRPI0712073A BRPI0712073A2 BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2 BR PI0712073 A BRPI0712073 A BR PI0712073A BR PI0712073 A2 BRPI0712073 A2 BR PI0712073A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
producing cells
polypeptide
stop codon
splice
Prior art date
Application number
BRPI0712073-7A
Other languages
English (en)
Inventor
Endl Josef
Kopetzki Erhard
Ploettner Olivier
Schwarz Ursula
Tiefenthaler Georg
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of BRPI0712073A2 publication Critical patent/BRPI0712073A2/pt
Publication of BRPI0712073B1 publication Critical patent/BRPI0712073B1/pt
Publication of BRPI0712073B8 publication Critical patent/BRPI0712073B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

CÉLULAS PRODUTORAS DE POLIPEPTÍDIO. A presente invenção descreve um ácido nuclélco compreendendo, na direção 5' a 3': a) um primeiro ácido nucléico que codifica um polipeptídio heterólogo sem um códon de parada em fase de leitura, b) um segundo ácido nucléico começando com um sítio doador de splice 5' e terminado por um sítio receptor de splice 3' compreendendo um códon de parada de tradução em fase de leitura e um sinal de poliadenilação, e c) um ácido nucléico que codifica i) pelo menos um fragmento de um domínio transmembrana, ou ii) um peptídio de sinal para uma âncora GPI.
BRPI0712073A 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga BRPI0712073B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06010146.6 2006-05-17
EP06010146 2006-05-17
PCT/EP2007/004313 WO2007131774A1 (en) 2006-05-17 2007-05-15 Polypeptide producing cells

Publications (3)

Publication Number Publication Date
BRPI0712073A2 true BRPI0712073A2 (pt) 2012-03-06
BRPI0712073B1 BRPI0712073B1 (pt) 2019-11-12
BRPI0712073B8 BRPI0712073B8 (pt) 2021-05-25

Family

ID=37076089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712073A BRPI0712073B8 (pt) 2006-05-17 2007-05-15 ácido nucléico para produção de um polipeptídio ou proteína heteróloga

Country Status (12)

Country Link
US (2) US8354516B2 (pt)
EP (2) EP2208792B1 (pt)
JP (1) JP4870208B2 (pt)
KR (1) KR101202498B1 (pt)
CN (1) CN101410525B (pt)
AU (1) AU2007251766B2 (pt)
BR (1) BRPI0712073B8 (pt)
CA (1) CA2651478C (pt)
ES (2) ES2573027T3 (pt)
IL (1) IL193721A (pt)
MX (1) MX2008013514A (pt)
WO (1) WO2007131774A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4870208B2 (ja) * 2006-05-17 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
ES2413379T3 (es) * 2008-08-28 2013-07-16 Novartis Ag Presentación en la superficie celular de isoformas polipeptídicas mediante ultralectura de codón de terminación
MX2011009025A (es) 2009-02-27 2011-09-28 Novartis Ag Sistema de vector de expresion que comprende dos marcadores de seleccion.
FR2944016B1 (fr) 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944017B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides eclaircissants activateurs du proteasome et compositions les contenant
FR2944018B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944798B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques eclaircissants activateurs du proteasome et compositions les contenant
FR2944797B1 (fr) 2009-04-23 2013-05-10 Isp Investments Inc Hydrolysats peptidiques activateurs du proteasome et compositions les contenant
CN101875916B (zh) * 2009-11-27 2013-04-17 西安交通大学 一种fgfr1高表达的重组hek293细胞及其应用
AU2013349844B2 (en) 2012-11-20 2017-03-02 Novartis Ag Optimized expression cassette for expressing a polypeptide with high yield
WO2014126254A1 (ja) * 2013-02-18 2014-08-21 協和発酵キリン株式会社 膜結合型タンパク質発現ベクター
EP2970956A1 (en) 2013-03-11 2016-01-20 Novartis AG Method of screening cell clones
WO2014171826A1 (en) 2013-04-17 2014-10-23 Stichting Vu-Vumc Treatment of cognitive impairment in depressive disorders
ES2689136T3 (es) 2013-07-31 2018-11-08 Novartis Ag Nuevos vectores de selección y métodos de selección de células hospedadoras eucariotas
PL3083677T3 (pl) 2013-12-20 2020-03-31 Novartis Ag Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania
KR102288857B1 (ko) 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법
BR112016019832A2 (pt) * 2014-02-28 2017-10-17 Glenmark Pharmaceuticals Sa constructo de expressão, polinucleotídeo, vetor de expressão ou clonagem, célula hospedeira, método para produzir um polipeptídio e método para selecionar uma célula hospedeira
DK3320099T3 (da) * 2015-07-09 2023-12-11 Inst Nat Sante Rech Med Membranforankret eller udskilt antistof til ekspression af lentivirale vektorer
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
WO2018060239A1 (en) 2016-09-29 2018-04-05 F. Hoffmann-La Roche Ag Improved method for selecting polypeptide producing cells
AU2017346885B2 (en) 2016-10-18 2021-10-21 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019015677A1 (en) * 2017-07-21 2019-01-24 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN ANIMALS
CN107557367B (zh) * 2017-09-08 2020-11-03 北京大学人民医院 Ighg1基因突变体及其应用
CN116761891A (zh) * 2020-12-01 2023-09-15 苏黎世联邦理工学院 包括可变启动子的dna构建体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
IL104570A0 (en) * 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DK1196566T3 (da) 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
IL136459A0 (en) * 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20030033616A1 (en) 2001-07-30 2003-02-13 Star-Lack Joshua Morris Imaging marker transgenes
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
EP1477805A1 (de) 2003-05-12 2004-11-17 ProBioGen AG Verfahren zur Zellselektion
EP1664774A4 (en) 2003-08-29 2007-06-27 Centocor Inc RAPID MEANS FOR OBTAINING HIGH-EXPRESSION CLONES OF MAMMALIAN CELLS, ACCORDING TO A METHYLCELLULOSE SCREENING METHOD AND IMMUNOPRECIPITATION
ATE417066T1 (de) * 2003-10-16 2008-12-15 Claude Negrier Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
AU2005222963B2 (en) * 2004-03-15 2009-10-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
JP4870208B2 (ja) * 2006-05-17 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞

Also Published As

Publication number Publication date
KR20090003327A (ko) 2009-01-09
IL193721A (en) 2014-09-30
US20130109058A1 (en) 2013-05-02
CA2651478A1 (en) 2007-11-22
EP2208792B1 (en) 2015-05-06
MX2008013514A (es) 2008-10-28
AU2007251766B2 (en) 2013-06-20
ES2543629T3 (es) 2015-08-20
EP2027273B1 (en) 2016-04-13
EP2208792A2 (en) 2010-07-21
EP2208792A3 (en) 2010-10-27
WO2007131774A1 (en) 2007-11-22
ES2573027T3 (es) 2016-06-03
US20090311725A1 (en) 2009-12-17
IL193721A0 (en) 2011-08-01
BRPI0712073B1 (pt) 2019-11-12
EP2027273A1 (en) 2009-02-25
US8354516B2 (en) 2013-01-15
US8541204B2 (en) 2013-09-24
CN101410525B (zh) 2012-09-05
JP4870208B2 (ja) 2012-02-08
CN101410525A (zh) 2009-04-15
KR101202498B1 (ko) 2012-11-16
BRPI0712073B8 (pt) 2021-05-25
JP2009537124A (ja) 2009-10-29
AU2007251766A1 (en) 2007-11-22
CA2651478C (en) 2015-02-03

Similar Documents

Publication Publication Date Title
BRPI0712073A2 (pt) cÉlulas produtoras de polipeptÍdio
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
BRPI0416544A (pt) proteìna de ligação de gag
CO6491105A2 (es) Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
CL2009000284A1 (es) Antagonistas especificos de pro-proteina convertasa subtilisina-kexina tipo 9 humana (pcsk9), composicion farmaceutica que lo comprende; acidos nucleicos que lo codifican; vector, celula y proceso para producir dicho antagonista; util para mejorar un trastorno, afeccion o enfermedad inducida por pcsk9.
BR112012008862A2 (pt) métodos para produzir uma glicoproteína recombinante e uma eritropoietina humana madura, e, composição
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
BR112014006509A2 (pt) fibras finas fabricadas a partir de polímero reticulado com composição de aldeído resinoso
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
BR112014017165A2 (pt) polipeptídeos de fator quimérico viii e seus usos
PE20140218A1 (es) Composicion farmaceutica
CU24058B1 (es) Antagonistas de pcsk9
MX2007015931A (es) Receptores de sabor dulce-umami y umami-dulce humanos quimericos.
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
BRPI0914969A2 (pt) método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
BR112012008665A2 (pt) tratamento de câncer
MX2010003526A (es) Ensamble para refuerzo de hormigon y marcadores.
BR112013021937A2 (pt) folha, artigo compósito moldado como uma sola de sapato, e processo para produzir um artigo compósito moldado como uma sola de sapato
UA110323C2 (en) Derivative of serum amyloid p and their receipt and application
BR112013002062A2 (pt) peça combustível e processo de produção de uma peça de combustível
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2723 DE 14-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.